Critical Factors for the Reversal of Methotrexate Cytotoxicity by Folinic Acid

Overview

Journal Br J Cancer

Specialty Oncology

Date 1991 Feb 1

PMID 1997110

Citations 3

Authors

S Bernard

M C Etienne

J L Fischel

P Formento

G Milano

Affiliations

Soon will be listed here.

Abstract

The cytotoxicity of methotrexate (MTX) on representative human tumour cell lines (two cell lines from head and neck carcinomas, two from breast carcinomas, two from osteosarcomas and one lymphoblastoid cell line) was evaluated to: (1) examine the optimal time interval between MTX and folinic acid (FA) administration; (2) determine the critical FA/MTX concentration ratios; and (3) compare the relative effects of the equimolar mixture d,I-FA and I-FA. The cytotoxic effects of MTX were assessed by the MTT semi-automated test. For all of the cell lines tested, a significant inverse relationship was noted between the degree of MTX cytotoxicity reversal and the duration of the time interval between MTX and FA administration. Overall an 18-24 h interval between MTX and FA represented a time-threshold after which MTX effects could not efficiently be reversed by FA in most cell lines. With shorter time intervals between MTX and FA, MTX cytotoxicity could be partially on even totally reversed by FA; the intensity of reversal varied among the cell lines tested, and depended on the FA/MTX ratio. Regardless of the interval between MTX and FA, analysis of the various FA/MTX ratios revealed a significant direct relationship between this ratio and the percentage of recovery. Presence of the d-form had no influence on the MTX rescue capacity of the I-form; this suggests that the presence of the d-FA is unlikely to have any significant clinical consequences.

Citing Articles

Mechanism of Action of Methotrexate Against Zika Virus.

Beck S, Zhu Z, Oliveira M, Smith D, Rich J, Bernatchez J Viruses. 2019; 11(4).

PMID: 30974762 PMC: 6521145. DOI: 10.3390/v11040338.

Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma.

Park J, Shin H Blood Res. 2016; 51(1):50-7.

PMID: 27104192 PMC: 4828529. DOI: 10.5045/br.2016.51.1.50.

Glucarpidase to combat toxic levels of methotrexate in patients.

Green J Ther Clin Risk Manag. 2012; 8:403-13.

PMID: 23209370 PMC: 3511185. DOI: 10.2147/TCRM.S30135.

References

Milano G, Thyss A, Renee N, Vallicioni J, Santini J, Schneider M . Altered pharmacokinetics and clinical consequences of low dose methotrexate plus cisplatin in the treatment of advanced head and neck cancer. Eur J Cancer Clin Oncol. 1986; 22(7):843-7. DOI: 10.1016/0277-5379(86)90372-x. View

Jaffe N, Robertson R, Ayala A, Wallace S, Chuang V, Anzai T . Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol. 1985; 3(8):1101-4. DOI: 10.1200/JCO.1985.3.8.1101. View

Borsi J, MOE P . A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer. 1987; 60(1):5-13. DOI: 10.1002/1097-0142(19870701)60:1<5::aid-cncr2820600103>3.0.co;2-d. View

Twentyman P, LUSCOMBE M . A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987; 56(3):279-85. PMC: 2002206. DOI: 10.1038/bjc.1987.190. View

Diddens H, Teufel T, Niethammer D . High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines. Cancer Chemother Pharmacol. 1987; 20(2):128-32. DOI: 10.1007/BF00253966. View

Ackland S, Schilsky R . High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987; 5(12):2017-31. DOI: 10.1200/JCO.1987.5.12.2017. View

Schroder H, Jensen K, Brandsborg M . Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions. Br J Clin Pharmacol. 1987; 24(4):537-41. PMC: 1386317. DOI: 10.1111/j.1365-2125.1987.tb03208.x. View

Gioanni J, Fischel J, Lambert J, Demard F, Mazeau C, Zanghellini E . Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol. 1988; 24(9):1445-55. DOI: 10.1016/0277-5379(88)90335-5. View

Schilsky R, Choi K, Vokes E, Guaspari A, Guarnieri C, Whaling S . Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer. 1989; 63(6 Suppl):1018-21. DOI: 10.1002/1097-0142(19890315)63:6+<1018::aid-cncr2820631305>3.0.co;2-s. View

10.

Bertrand R, Jolivet J . Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst. 1989; 81(15):1175-8. DOI: 10.1093/jnci/81.15.1175. View

11.

Newman E, Straw J, Doroshow J . Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res. 1989; 49(20):5755-60. View

12.

Browman G, Goodyear M, Levine M, Russell R, Archibald S, Young J . Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol. 1990; 8(2):203-8. DOI: 10.1200/JCO.1990.8.2.203. View

13.

Pinedo H, ZAHARKO D, Bull J, Chabner B . The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 1976; 36(12):4418-24. View

14.

Stoller R, Hande K, Jacobs S, Rosenberg S, Chabner B . Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977; 297(12):630-4. DOI: 10.1056/NEJM197709222971203. View

15.

Sirotnak F, Moccio D, Dorick D . Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res. 1978; 38(2):345-53. View

16.

Warren R, Nichols A, Bender R . Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res. 1978; 38(3):668-71. View

17.

Stoller R, Kaplan H, CUMMINGS F, Calabresi P . A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. Cancer Res. 1979; 39(3):908-12. View

18.

Rosen G, Caparros B, Huvos A, Kosloff C, Nirenberg A, Cacavio A . Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49(6):1221-30. DOI: 10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e. View

19.

Evans W, Hutson P, Stewart C, Cairnes D, Bowman W, Rivera G . Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther. 1983; 33(3):301-7. DOI: 10.1038/clpt.1983.37. View

20.

Jolivet J, Cowan K, Curt G, Clendeninn N, Chabner B . The pharmacology and clinical use of methotrexate. N Engl J Med. 1983; 309(18):1094-104. DOI: 10.1056/NEJM198311033091805. View